Skip To Main Content
Nabeel El-Bardeesy on Muck Rack

Nabeel El-Bardeesy

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nabeel

Contact Nabeel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity - Nature

|
By Christina Baumgartner, Arvin Iracheta-Vellve, Kira E. Olander, Omar Ávila, Audrey J. Muscato, James C. Patti, Domenick E. Kennedy, Matthew Rees, Melissa Ronan, Jennifer Roth, Meng-Ju Wu, Nelson H. Knudsen, Debattama R. Sen, Todd Golub, Elliot P Farney, Kathleen B. Yates, Ashwin V. Kammula, Nabeel El-Bardeesy, Philip R. Kym
| Nature Verified
Abstract Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2. The protein tyrosine phosphatases PTPN2 and PTPN1 are central regulators of inflammation, and their genetic deletion in either tumour cells or immune cells promotes anti-tumour immunity3,4,5,6. However, phosphatases are challenging drug targets; in particular, the active site has been considered undruggable.
Open in Who Shared Issue with article?
See all 1 articles